© BioMed Central Ltd 2001
Published: 17 September 2001
If clinicians could predict how a cancer patient would respond to specific chemotherapeutic drugs, they would be able to choose an individualized treatment protocol with greater chances of success and minimized side effects. In the September 11 Proceedings of the National Academy of Sciences, Jane Staunton and colleagues from the Whitehead Institute, Cambridge, Massachusetts describe a genomic approach for predicting chemosensitivity (Proc Natl Acad Sci USA 2001, 98:10787-10792). They measured the expression levels of almost 7,000 genes in the sixty cancer cell lines of the NCI-60 panel from the National Cancer Institute's Developmental Therapeutics Program. They then used these microarray data to define sets of genes that could predict sensitivity to over 200 chemical compounds. Gene-drug relationships allowed the definition of a chemosensitivity classifier to predict the cytotoxicity of different compounds.